Molecular Systems Design & Engineering,
Год журнала:
2024,
Номер
9(8), С. 800 - 813
Опубликована: Янв. 1, 2024
Antibiotics
are
the
main
strategy
to
treat
bacterial
infections,
but
can
cause
resistance.
We
comprehensively
summarize
work
on
fabrication
of
photothermal
antibacterial
platforms
for
infectious
skin
wound
healing.
The
use
of
traditional
Ag-based
antibacterial
agents
is
usually
accompanied
by
uncontrollable
silver
release,
which
makes
it
difficult
to
find
a
balance
between
performance
and
biosafety.
Herein,
we
prepared
core-shell
system
ZIF-8-derived
amorphous
carbon-coated
Ag
nanoparticles
(Ag@C)
as
an
ideal
research
model
reveal
the
synergistic
effect
structure-activity
relationship
structural
transformation
carbon
shell
core
on
regulation
release
behavior.
It
found
that
Ag@C
at
600
°C
(AC6)
exhibits
best
ion
kinetics
due
combination
relatively
simple
structure
lower
crystallinity
core,
thereby
exerting
stronger
properties
(>99.999
%)
trace
doses
(20
μg
mL
Digestive
system
diseases,
such
as
gastritis,
gastric
ulcers,
chronic
liver
disease,
inflammatory
bowel
disease
(IBD),
and
colorectal
cancer,
represent
a
major
group
of
diseases
that
have
high
morbidity
death
rates
worldwide.
Their
incidence
continues
to
rise
owing
factors
dietary
structure
changes,
accelerated
lifestyles,
increased
environmental
pollution,
population
aging.
Despite
the
rapid
development
medical
technology,
treatment
digestive
still
faces
many
challenges,
addressing
drug-resistant
Helicobacter
pylori
infections,
treating
IBD,
improving
efficacy
advanced
gastrointestinal
tumor
therapies.
Fortunately,
emergence
drug-releasing
materials
has
provided
new
insights
can
be
used
in
disorders.
Drug-releasing
are
category
specially
designed
carriers
or
systems
capable
carrying
drugs
controlling
their
release
at
specific
time
intervals
on
demand
achieve
desired
therapeutic
effect.
This
article
reviews
recent
research
progress
diagnose
treat
First,
limitations
traditional
oral
drug
delivery
methods,
low
bioavailability
nonspecific
distribution,
discussed.
Second,
different
types
materials,
liposomes,
dendritic
polymers,
micelles,
nanogels,
inorganic
nanoparticles,
extracellular
vesicles,
along
with
advantages
terms
improved
stability,
biocompatibility,
targeting,
controlled
release,
outlined.
In
addition,
application
strategies
preclinical
findings
various
for
disorders
discussed
detail.
Review
could
help
researchers
explore
more
nanomaterials
personalized
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 29, 2024
Abstract
Colorectal
cancer
(CRC)
is
a
leading
cause
of
cancer-related
mortality,
with
Fusobacterium
nucleatum
(
F.
)
identified
as
key
contributor
to
its
progression.
This
study
explores
novel
targeted
therapy
using
bioengineered
probiotics
expressing
guided
antimicrobial
peptides
(gAMPs)
selectively
inhibit
.
We
engineered
Lactococcus
lactis
MG1363
express
gAMPs
derived
from
Ovispirin
and
Cathelin-related
peptide
SCF,
linked
Statherin-derived
guide
(YQPVPE)
that
binds
specifically
the
membrane
porin
FomA.
Our
results
demonstrate
enhances
binding
affinity
,
significantly
increasing
preferential
attachment
compared
control
peptides.
In
vitro
assays
revealed
both
unguided
AMPs
effectively
inhibited
biofilm
formation
in
showing
reduced
toxicity
against
non-target
bacteria
Bacteroides
fragilis
Escherichia
coli
).
The
were
also
more
effective
modulating
growth
kinetics,
exhibiting
selective
towards
at
lower
concentrations.
Co-culture
experiments
simulated
human
gut
microbiome
demonstrated
gAMP
probiotic
maintained
microbial
diversity
while
reducing
abundance.
Quantitative
PCR
16S
rRNA
sequencing
confirmed
treatment
preserved
richness
microbiota,
contrasting
significant
dysbiosis
observed
samples.
These
findings
support
potential
therapeutic
approach
combat
-associated
CRC.
By
leveraging
specificity
peptides,
this
strategy
not
only
addresses
pathogenicity
but
mitigates
adverse
effects
traditional
therapies
on
beneficial
microbiota.
Future
studies
will
explore
clinical
applicability
CRC
management
impact
overall
health.
